6Johnson TS. Haylor JL. Thomas GL. et al. Matrix Metallo Proteinases and Their Inhibitions in Experimental Renal Scarring Exp Nephrol, 2002,10: 182-195.
4Maki U, Shoji K, Takashi K, et al. Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant, 2002, 17:1189-1196.
5Rougier JP, Moullier P, Piedagnel R, et al. Hypemsmolality suppresses but TGF-β1 increases MMP-9 in human peritoneal mesothelial cells. Kidney Int,1997,51:337-347.
6Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis, 2001, 21: 373-384.
7McLennan SV, Kelly DJ, Cox A J, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.Diabetologia, 2002, 45: 268-274.
8Baricos WH, Cortez SL, EI-Dahr SS, et al. ECM degradation by cultured human mesangial cells is mediated by a PA /plasmin/MMP2 cascade. Kidney Int, 1995,47: 1039-1047.
9Tmleber FR. Bslkwill: Regulation of monocyte MMP-9 production by TNF-α and a tumour derived souble factor (MMPsF). Brtish Journal of Cancer, 1998,78.. 724-732.
10Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase-4. J Biol Chem, 1996,271 : 30375-30380.
